Region Jaemtland Haerjedalen

The site is conducting studies that aim to find safer oral step‑down regimens for multidrug‑resistant urinary tract infections and to improve outcomes for patients with serious bloodstream infections caused by Staphylococcus aureus.

• Alternative antibiotics for ESBL‑producing urinary tract infections
• Staphylococcus aureus Network Adaptive Platform trial (SNAP)
• Evaluation of novel therapeutic approaches for resistant bacterial infections

Östersunds sjukhus is leveraging its microbiology expertise to reduce reliance on traditional drugs and curb antimicrobial resistance.

Research focuses on reducing the burden of atherosclerotic cardiovascular disease and acute cardiac events by testing innovative pharmacologic strategies, including therapies for Takotsubo syndrome and early lipid management after myocardial infarction.

• Optimized pharmacologic treatment for broken heart (Takotsubo) syndrome
• EVOLVE-MI trial evaluating evolocumab in acute myocardial infarction
• AZD0780 impact on major adverse cardiovascular events (MACE‑PLUS)
• Apixaban versus no antithrombotic therapy for thromboembolic prevention

The cardiovascular program at the hospital seeks to improve survival and quality of life for patients with high‑risk heart disease.

Studies are evaluating whether outpatient labour induction can be as safe and effective as traditional inpatient care, while also assessing strategies to prevent and treat HPV infection and cervical neoplasia.

• OPTION – Outpatient induction of labour trial
• Concomitant HPV vaccination and screening for rapid elimination of infection
• FI-3 study on ICEF15 therapy for fecal incontinence in women

Östersunds sjukhus collaborates with national screening programs to enhance women’s health outcomes.

The research agenda includes evaluating intravenous immunoglobulin as an adjunct therapy for patients with severely impaired B‑cell function and COVID‑19, and testing baricitinib to preserve pancreatic β‑cell function in newly diagnosed type 1 diabetes.

• IVIG add‑on versus standard of care for COVID‑19 with B‑cell impairment
• Baricitinib trial to protect β‑cell function in type 1 diabetes
• Adenosine and dipyridamole study in Takotsubo syndrome (immune modulation)

The department’s immunology team aims to strengthen therapeutic options for both infectious and autoimmune conditions.

Clinical work is centered on minimally invasive approaches for scrotal conditions such as hydrocele and spermatocele, as well as optimized antibiotic regimens for male urinary tract infections.

• Sclerotherapy of hydrocele and spermatocele with Aetoxysclerol ± ethanol
• Comparative anesthesia techniques for scrotal procedures
• Non‑inferiority study of oral step‑down therapy for ESBL‑UTIs in men

Östersunds sjukhus provides a dedicated urology service focused on patient comfort and rapid recovery.

Ongoing investigations assess pain management strategies and functional outcomes after procedures that may affect the musculoskeletal system, including scrotal sclerotherapy and postoperative care.

• Analgesic protocols for sclerotherapy‑related pain
• Evaluation of local versus systemic anesthesia in minor urologic surgeries
• Functional recovery monitoring after minimally invasive scrotal interventions

The multidisciplinary team integrates physiotherapy insights to enhance postoperative mobility.

Trials target advanced cancers, notably HER2‑mutated non‑small cell lung cancer, while also supporting public health initiatives to curb virus‑related malignancies such as those driven by HPV.

• Sevabertinib efficacy and safety in HER2‑mutated NSCLC
• Population‑level HPV vaccination and screening impact study
• Assessment of novel targeted agents in solid tumors

The oncology program at Östersunds sjukhus combines precision medicine with preventive strategies.

Research includes preserving pancreatic function in type 1 diabetes and improving lipid profiles in acute cardiac settings, aiming to reduce long‑term metabolic complications.

• Baricitinib preservation of β‑cell function in newly diagnosed type 1 diabetes
• Evolocumab plus routine lipid management in acute myocardial infarction
• Aliskiren versus enalapril in complement‑mediated renal disease (metabolic impact)

The metabolic unit collaborates across specialties to address both endocrine and cardiovascular risk factors.

Studies focus on improving quality of life for patients experiencing fecal incontinence and severe respiratory symptoms, such as those seen in eosinophilic asthma.

• ICEF15 therapy for fecal incontinence due to anal sphincter dysfunction
• GSK3511294 comparison with existing anti‑IL‑5/5R biologics in severe asthma
• Symptom score assessment after scrotal sclerotherapy

By targeting both functional impairment and inflammatory symptoms, the site seeks to deliver comprehensive patient‑centered care.

The department evaluates advanced biologic therapies for severe eosinophilic asthma and investigates immunoglobulin supplementation for patients with compromised immunity due to COVID‑19.

• Non‑inferiority study of GSK3511294 versus mepolizumab/benralizumab
• IVIG add‑on trial for COVID‑19 patients with B‑cell dysfunction
• Biomarker analysis of eosinophilic inflammation in asthma

Respiratory specialists at the hospital aim to reduce exacerbations and enhance recovery in high‑risk populations.

Clinical work addresses viral pathogens by testing immunomodulatory treatments for COVID‑19 and by implementing nationwide strategies to accelerate the elimination of HPV infection.

• Randomized trial of IVIG as adjunct therapy for COVID‑19 with severe B‑cell impairment
• Concomitant HPV vaccination and screening program evaluation
• Investigation of antiviral adjuncts in virus‑associated respiratory illness

Östersunds sjukhus collaborates with public health agencies to translate trial findings into community‑level interventions.